NASDAQ:OXFDOxford Immunotec Global Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oxford Immunotec Global PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.78 +0.11 (+1.14 %) (As of 04/7/2020 03:07 PM ET) Add Compare Share Today's Range$9.78Now: $9.78▼$10.2550-Day Range$9.15MA: $11.96▼$14.9852-Week Range$8.37Now: $9.78▼$17.77Volume18,852 shsAverage Volume315,236 shsMarket Capitalization$256.24 millionP/E RatioN/ADividend YieldN/ABeta0.8 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. The company develops and markets T-SPOT.TB test used to test for tuberculosis. It is also developing C6 Borrelia burgdorferi (Lyme) ELISA kit, which measures Lyme specific antibodies; and T-SPOT.CMV test that utilizes its T-SPOT technology platform to measure the strength of a patient's cellular immune response to antigens specific to cytomegalovirus (CMV), as well as provides information for informing management strategies of patients at risk of CMV infection and disease, such as transplant patients. The company markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors internationally. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOxford Immunotec Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Oxford Immunotec Global has a potential upside of 104.5% from its current price of $9.78.Amount of Analyst CoverageOxford Immunotec Global has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesOxford Immunotec Global has received 260 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOxford Immunotec Global has received 267 “underperform” votes. (Add your “underperform” vote.)Community SentimentOxford Immunotec Global has received 50.66% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote “Outperform” if you believe OXFD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOxford Immunotec Global does not currently pay a dividend.Dividend GrowthOxford Immunotec Global does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oxford Immunotec Global insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.21% of the stock of Oxford Immunotec Global is held by insiders.Percentage Held by Institutions92.75% of the stock of Oxford Immunotec Global is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Oxford Immunotec Global are expected to decrease by -272.73% in the coming year, from ($0.11) to $0.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oxford Immunotec Global is -139.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oxford Immunotec Global is -139.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOxford Immunotec Global has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OXFD Previous Symbol CUSIPN/A CIK1586049 Webhttp://www.oxfordimmunotec.com/ Phone44-0-12-3544-2780Debt Debt-to-Equity Ratio0.04 Current Ratio15.62 Quick Ratio14.82Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$73.71 million Price / Sales3.48 Cash Flow$0.02 per share Price / Cash Flow610.90 Book Value$8.08 per share Price / Book1.21Profitability EPS (Most Recent Fiscal Year)($0.05) Net Income$-1,810,000.00 Net Margins-2.45% Return on Equity-0.62% Return on Assets-0.56%Miscellaneous Employees215 Outstanding Shares26,200,000Market Cap$256.24 million Next Earnings Date5/14/2020 (Estimated) OptionableNot Optionable Receive OXFD News and Ratings via Email Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:OXFD Rates by TradingView Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions How has Oxford Immunotec Global's stock been impacted by COVID-19 (Coronavirus)? Oxford Immunotec Global's stock was trading at $12.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OXFD shares have decreased by 19.8% and is now trading at $9.78. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Oxford Immunotec Global? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Oxford Immunotec Global. When is Oxford Immunotec Global's next earnings date? Oxford Immunotec Global is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Oxford Immunotec Global. How were Oxford Immunotec Global's earnings last quarter? Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its earnings results on Monday, March, 2nd. The company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.04. The company earned $18.11 million during the quarter, compared to the consensus estimate of $17.29 million. Oxford Immunotec Global had a negative return on equity of 0.62% and a negative net margin of 2.45%. View Oxford Immunotec Global's earnings history. What guidance has Oxford Immunotec Global issued on next quarter's earnings? Oxford Immunotec Global issued an update on its first quarter 2020 IntraDay earnings guidance on Friday, April, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14.1-14.1 million, compared to the consensus revenue estimate of $12.89 million. What price target have analysts set for OXFD? 2 Wall Street analysts have issued 12 month price objectives for Oxford Immunotec Global's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Oxford Immunotec Global's share price to reach $20.00 in the next year. This suggests a possible upside of 104.5% from the stock's current price. View analysts' price targets for Oxford Immunotec Global. Has Oxford Immunotec Global been receiving favorable news coverage? News headlines about OXFD stock have trended very negative recently, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oxford Immunotec Global earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutOxford Immunotec Global. Are investors shorting Oxford Immunotec Global? Oxford Immunotec Global saw a increase in short interest in March. As of March 13th, there was short interest totaling 422,500 shares, an increase of 10.7% from the February 27th total of 381,800 shares. Based on an average daily volume of 126,900 shares, the short-interest ratio is presently 3.3 days. Approximately 1.8% of the shares of the company are short sold. View Oxford Immunotec Global's Current Options Chain. Who are some of Oxford Immunotec Global's key competitors? Some companies that are related to Oxford Immunotec Global include Intellia Therapeutics (NTLA), Heska (HSKA), Lantheus (LNTH), Quotient (QTNT), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Trinity Biotech (TRIB), GeneNews (GNWSF), Achieve Life Sciences (ACHV), Akers Biosciences (AKER) and Arca Biopharma (ABIO). What other stocks do shareholders of Oxford Immunotec Global own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Immunomedics (IMMU), AbbVie (ABBV), Intel (INTC), Gold Resource (GORO), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Gilead Sciences (GILD), Halozyme Therapeutics (HALO), Sangamo Therapeutics (SGMO) and Advanced Micro Devices (AMD). Who are Oxford Immunotec Global's key executives? Oxford Immunotec Global's management team includes the following people: Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 45)Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 58)Mr. Matthew T.E. McLaughlin, Chief Financial Officer (Age 42)Mr. Stefan C. Linn, Chief Operating Officer (Age 54)Ms. Karen C. Koski, VP of Strategy & Investor Relations What is Oxford Immunotec Global's stock symbol? Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD." How do I buy shares of Oxford Immunotec Global? Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Oxford Immunotec Global's stock price today? One share of OXFD stock can currently be purchased for approximately $9.78. How big of a company is Oxford Immunotec Global? Oxford Immunotec Global has a market capitalization of $256.24 million and generates $73.71 million in revenue each year. The company earns $-1,810,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe. View additional information about Oxford Immunotec Global. What is Oxford Immunotec Global's official website? The official website for Oxford Immunotec Global is http://www.oxfordimmunotec.com/. How can I contact Oxford Immunotec Global? Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: What is a support level?
